| |
VIAGRA
CASE EVALUATION
Please
fill out the form below to have your case evaluated.
About
Viagra:
In a recent study, US researchers describe seven patients
who developed nonarteritic ischemic optic neuropathy (NAION),
an eye ailment that can result in permanent vision loss, after
taking Viagra (sildenafil) for erection difficulties. Combined
with past reports, this study brings the total number of sildenafil-related
NAION cases to 14.
"For
years, we've known that a number of men who take Viagra will
experience short-term color changes in their vision and see
things as green or blue," study co-author Dr. Howard
D. Pomeranz, from the University of Minnesota in Minneapolis,
said in a statement. With the exception of one patient whose
symptoms began 24 to 36 hours after using Viagra, the patients
developed symptoms within 24 hours of use.
In all
patients, the initial symptoms were blurred vision and some
degree of vision loss. In one patient, both eyes were affected,
whereas in the remainder, just one was involved. Three patients
had preexisting eye problems that may have increased their
risk of NAION.
Viagra
News May 27, 2005
Pfizer
Inc., the world's largest drugmaker, said U.S. regulators
may require a label warning that the Viagra impotence drug
has been linked to reports of blindness and vision loss in
at least one in a million users.
The FDA
has 38 reports of the blindness, among users of Viagra. Pfizer
spokesman Daniel Watts confirmed Friday that the drugmaker
was in discussions with the FDA about adding a disclosure
to Viagra's label to say that in rare cases, men taking Viagra
had developed blindness.
Viagra
was approved by the government in 1998. It may aid in the
treatment of enlarged hearts that can result from high blood
pressure, tests on animals indicate.
The transmission of this e-mail does not create an attorney-client relationship
between the sender and Kalfus & Nachman. See Disclaimer
Call Kalfus &
Nachman at 1-888-HURTLINE For your free legal
consultation or save time with this online Contact Form. |
|